Anticandidal Agents
Academic Press Inc (Verlag)
978-0-12-811311-0 (ISBN)
Candida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines.
Lately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics.
Dr. Awanish Kumar is currently an Associate Professor in the Department of Biotechnology at the National Institute of Technology, Raipur (CG), India. He has more than 13 years of research experience. He received his PhD in Molecular Parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. Dr. Kumar has served on various national and international organizations in different academic and research capacities. He has also served on many national committees and scientific advisory panels, as a member of many international professional research societies, and as a reviewer and editorial board member of reputed and refereed journals. He has authored or edited several monographs, books, and book chapters.
Chapter 1. Introduction
Chapter 2. Host–Pathogen Interaction
Chapter 3. Antifungals Used Against Candidiasis
Chapter 4. Drug Resistance in Candida
Chapter 5. Multidrug Resistance and Transporters
Chapter 6. Potential Anticandidal Targets
Chapter 7. Drug Development Strategies
Chapter 8. Conclusion
| Erscheinungsdatum | 29.09.2016 |
|---|---|
| Verlagsort | San Diego |
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Gewicht | 160 g |
| Themenwelt | Studium ► Querschnittsbereiche ► Infektiologie / Immunologie |
| Naturwissenschaften ► Biologie | |
| ISBN-10 | 0-12-811311-1 / 0128113111 |
| ISBN-13 | 978-0-12-811311-0 / 9780128113110 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
